高血压左心室肥厚患者血清可溶性基质溶素-2、半乳糖凝集素-3的临床价值研究

Clinical value research of serum soluble matrix lysin-2 and galectin-3 in patients with hypertensive left ventricular hypertrophy

目的探讨高血压左心室肥厚患者血清可溶性基质溶素-2(ST-2)、半乳糖凝集素-3(galectin-3)的临床价值。方法收集研究对象(健康对照组、高血压左心室肥厚组、高血压非左心室肥厚组)的临床资料并检测血清ST-2、galectin-3水平。分析二者与心脏超声指标的相关性及对左心室肥厚的预测价值。结果健康对照组、高血压非左心室肥厚组、高血压左心室肥厚组收缩压(SBP)、舒张压(DBP)、三酰甘油(TG)、室间隔厚度(IVST)、左心室质量指数(LVMI)、左心室后壁厚度(LVPWT)、左心室射血分数(LVEF)、ST-2、galectin-3水平呈升高趋势,差异有统计学意义(P<0.05)。高血压左心室肥厚组血清ST2、galectin-3水平与LVMI、IVST、LVPWT呈正相关(P<0.05)。血清galectin-3、ST2预测左心室肥厚的曲线下面积(AUC)分别为0.868和0.890。结论高血压左心室肥厚患者血清ST2、galectin-3水平升高,二者与心脏超声指标相关,对左心室肥厚有一定预测潜能。

Objective To investigate the clinical value of serum soluble matrix lysin-2(ST-2),galectin-3(galectin-3)in patients with hypertensive left ventricular hypertrophy.Methods The clinical data of subjects(healthy control group,hypertensive left ventricular hypertrophy group and hypertensive non left ventricular hypertrophy group)were collected,and serum ST-2 and galectin-3 levels were detected.The correlation between them and echocardiographic parameters and their predictive value for left ventricular hypertrophy were analyzed.Results Systolic pressure(SPB),diastolic pressure(DBP),triacylglycerol(TG),interventricular septum thickness(IVST),left ventricular mass index(LVMI),left ventricular posterior wall thickness(LVPWT),left ventricular ejection fractions(LVEF),ST-2 and galectin-3 increased in healthy control group,hypertensive non left ventricular hypertrophy group and hypertensive left ventricular hypertrophy group(P<0.05).Serum ST2 and galectin-3 levels were positively correlated with LVMI,IVST and LVPWT in hypertensive left ventricular hypertrophy group(P<0.05).The area under curve(AUC)of serum galectin-3 and ST2 were 0.868 and 0.890 in predicting left ventricular hypertrophy.Conclusion The serum ST2 and galectin-3 levels in patients with hypertension and left ventricular hypertrophy increase,and are correlated with echocardiographic indexes,which has certain predictive potential for left ventricular hypertrophy.